Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status.

Cancers (Basel) · 2024 · PMC11119071 · PMID 38791905

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The review found that although indirect comparisons suggested that nivolumab plus ipilimumab may offer a longer PFS compared to pembrolizumab, this difference did not reach statistical significance in our study.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.